Medical Literature Monitoring in Pharmacovigilance

Introduction

Scientific and medical literature has long been recognised as an important source of pharmacovigilance information.

Case reports, observational studies, case series and other publications may contain information relating to suspected adverse reactions that has not been reported through traditional spontaneous reporting channels.

Historically, Marketing Authorisation Holders (MAHs) were responsible for independently screening the scientific literature to identify reportable adverse reactions associated with their products.

This often resulted in substantial duplication of effort because multiple companies reviewed the same journals and publications for similar information.

To improve efficiency and consistency, the European Medicines Agency (EMA) introduced the Medical Literature Monitoring (MLM) programme.

Today, MLM forms an important component of the European pharmacovigilance system and contributes directly to EudraVigilance reporting activities.

Why Literature Monitoring Matters

Not all adverse reactions are reported directly to pharmaceutical companies or health authorities.

Many clinically important observations first appear in:

• Case reports
• Case series
• Observational studies
• Epidemiological research
• Clinical publications

Literature sources may reveal:

• Previously unknown adverse reactions
• Rare adverse reactions
• Changes in frequency
• Emerging risk factors
• Safety concerns in specific populations

Literature monitoring therefore represents an important component of signal detection and benefit-risk monitoring.

Historical Approach to Literature Surveillance

Before the MLM programme, every MAH generally maintained independent literature surveillance activities.

This approach presented several challenges:

• Duplication of effort
• Resource-intensive processes
• Inconsistent case identification
• Variable quality standards
• Repeated review of the same publications

Large journals might be screened by dozens of organisations simultaneously.

Although this approach ensured broad coverage, it was often inefficient.

What is Medical Literature Monitoring?

Medical Literature Monitoring is an EMA-operated programme under which designated literature sources are centrally monitored for selected active substances.

The EMA:

• Reviews designated publications
• Identifies potential adverse reaction reports
• Creates Individual Case Safety Reports
• Submits cases into EudraVigilance

The objective is to improve consistency and reduce duplication across the pharmacovigilance system.

MLM does not replace all literature surveillance activities.

Rather, it centralises specific responsibilities for designated substances and designated literature sources.

Which Products are Covered?

The MLM programme does not apply to every medicinal product.

Coverage is determined by the EMA and focuses on selected active substances.

The EMA publishes information regarding substances included within the programme.

MAHs should understand:

• Whether their products are included
• Which substances are monitored
• Which responsibilities remain with the MAH

Failure to understand programme scope may result in compliance gaps.

How MLM Cases Enter EudraVigilance

When EMA reviewers identify a reportable case within monitored literature:

1. The publication is assessed.
2. Relevant safety information is extracted.
3. An Individual Case Safety Report is created.
4. The report is entered into EudraVigilance.
5. The report becomes available to authorised users.

This process ensures that literature-derived safety information becomes available within the broader European pharmacovigilance ecosystem.

Downloading MLM Cases

Many pharmacovigilance professionals first encounter MLM through EudraVigilance case downloads.

Downloaded MLM cases may support:

• Signal detection
• Aggregate reporting
• Medical review
• Safety surveillance
• Benefit-risk assessment

Organisations should have procedures describing how downloaded MLM cases are managed within their pharmacovigilance systems.

Responsibilities of Marketing Authorisation Holders

One common misconception is that MLM eliminates literature surveillance responsibilities for MAHs.

This is incorrect.

MAHs remain responsible for understanding:

• Programme scope
• Product coverage
• Residual monitoring obligations
• Internal procedures

Responsibilities may include:

• Monitoring literature outside programme coverage
• Reviewing downloaded cases
• Supporting signal detection
• Maintaining documentation
• Ensuring procedural compliance

The precise responsibilities depend upon the products and substances involved.

Literature Cases and Signal Detection

Literature-derived cases can contribute significantly to signal detection activities.

Published case reports may:

• Identify new adverse reactions
• Support existing signals
• Provide mechanistic insights
• Highlight emerging clinical concerns

Consequently, literature information often plays an important role within signal management activities.

For a detailed discussion see:

[[evdas-and-signal-detection]]

Relationship Between MLM and EudraVigilance

MLM and EudraVigilance are closely connected.

A simplified relationship can be described as:

Together these systems support broader pharmacovigilance objectives.

QPPV Oversight

The QPPV is not generally expected to perform literature surveillance activities personally.

However, regulators typically expect the QPPV to understand:

• How literature monitoring is performed
• Which products are covered
• How literature cases are managed
• How signal detection activities utilise literature information
• Whether compliance risks exist

The QPPV should maintain visibility of significant issues affecting literature surveillance processes.

Inspection Perspective

Literature surveillance activities may be reviewed during pharmacovigilance inspections.

Inspectors may assess:

• Literature surveillance procedures
• Programme coverage assessments
• Documentation of responsibilities
• Management of downloaded MLM cases
• Governance arrangements
• Compliance monitoring activities

Inspectors generally expect organisations to demonstrate a clear understanding of their obligations.

Common Inspection Findings

Observed deficiencies may include:

• Unclear programme scope
• Incomplete procedures
• Failure to document responsibilities
• Inadequate oversight
• Failure to manage downloaded literature cases appropriately
• Insufficient governance controls

Many findings arise because organisations incorrectly assume that MLM removes all literature-related obligations.

Practical Considerations

Effective MLM governance commonly includes:

• Defined procedures
• Responsibility matrices
• Coverage assessments
• Periodic review activities
• Training programmes
• Compliance monitoring
• QPPV oversight

These activities help ensure that literature surveillance responsibilities remain appropriately controlled.

Key Takeaways

• Medical literature is an important source of pharmacovigilance information.
• The EMA operates the Medical Literature Monitoring programme for selected substances.
• MLM reduces duplication of effort across the pharmacovigilance system.
• Literature-derived cases are entered into EudraVigilance.
• MAHs continue to retain important literature surveillance responsibilities.
• Literature information contributes to signal detection and benefit-risk monitoring.
• QPPVs are expected to understand how literature monitoring activities are governed.
• Literature surveillance processes may be reviewed during inspections.

References

1. EMA Good Pharmacovigilance Practices (GVP) Module VI – Collection, Management and Submission of Reports of Suspected Adverse Reactions to Medicinal Products.
2. Regulation (EC) No 726/2004.
3. Directive 2001/83/EC.
4. Commission Implementing Regulation (EU) No 520/2012.
5. EMA Medical Literature Monitoring Guidance.
6. EMA EudraVigilance Documentation.
7. GVP Module IX – Signal Management.
8. ICH E2D Post-Approval Safety Data Management.